Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8CD69 T cellsShichuan Tang, Ruijing Tang, Geng Chen, Da Zhang, Kongying Lin, Huan Yang, Jun Fu, Yutong Guo, Fangzhou Lin, Xiuqing Dong, Tingfeng Huang, Jie Kong, Xiaowei Yin, Aimin Ge, Qizhu LinSee the full list of authors
18 December 2024
LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancerLiting Lv, Qing Miao, Sutong Zhan, Peilin Chen, Wei Liu, Jiawen Lv, Wenjie Yan, Dong Wang, Hongbing Liu, Jie Yin, Jian Feng, Yong Song, Mingxiang Ye, Tangfeng Lv
18 December 2024
Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapyZhi Ji, Xia Wang, Jiaqi Xin, Lijun Ma, Duo Zuo, Hongli Li, Lan Su, Xinze Lv, Shaohua Ge, Le Zhang, Yong Liu, Yanhui Zhang, Tingting Ding, Ting Deng, Yi BaSee the full list of authors
9 December 2024
Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cellsDaniel H Park, Pratik S Bhojnagarwala, Kevin Liaw, Devivasha Bordoloi, Nicholas J Tursi, Shushu Zhao, Zev A Binder, Donald O’Rourke, David B Weiner
2 December 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 studyCaicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, QiMing Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan LinSee the full list of authors
27 November 2024
Degradation of PARP1 by MARCHF3 in tumor cells triggers cCAS-STING activation in dendritic cells to regulate antitumor immunity in hepatocellular carcinomaJun Cao, Bingbing Su, Chi Zhang, Rui Peng, Daoyuan Tu, Qiangwei Deng, Guoqing Jiang, Shengjie Jin, Qian Wang, Dou-Sheng Bai
27 November 2024
Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancerBuhai Wang, Yichen Liang, Yuechao Wu, Qiuxian Li, Yichun Zeng, Liqin Liu, Wenmiao Cao, Xiaoru Geng, Yuxiang Huang, Yinxia Wu, Jiulin Pan, Xian Zhang, J Juan Gu
27 November 2024
Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trialJing Wang, Siqi Li, Hao Jiang, Ying-Jun Chang, Xiaosu Zhao, Jinsong Jia, Xiaolu Zhu, Lizhong Gong, Xiaohong Liu, Wenjing Yu, Xiaojun Huang
21 November 2024
Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapyTracee L McMiller, Sepideh Besharati, Mark Yarchoan, Qingfeng Zhu, Keziban Ünsal-Kaçmaz, Ke Xu, Junghwa Lee, Feriyl Bhaijee, Logan L Engle, Janis M Taube, Alan E Berger, Robert A Anders, Suzanne L Topalian
20 November 2024
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumorsMatthew H Taylor, Aung Naing, John Powderly, Paul Woodard, Luke Chung, Wen Hong Lin, Hongyu Tian, Nathan Siemers, Hong Xiang, Rong Deng, Kyu Hong, Donna Valencia, Tao Huang, Ying Zhu, X Charlene LiaoSee the full list of authors
20 November 2024